SCHEMBL5494654

SCHEMBL5494654

O=C(O)C1CSC(c2ccc(F)cc2)=N1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.45
BCL2L1 Q07817 1/20 0.42
BAD Q92934 1/20 0.42
APAF1 O14727 1/20 0.41
POLB P06746 1/20 0.41
GRK2 P25098 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
HTR2B P41595 1/20 0.39
MAPT P10636 2/20 0.38
TSHR P16473 1/20 0.38
LMNA P02545 1/20 0.37
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
CPA1 P15085 1/20 0.35
CSNK2A2 P19784 1/20 0.34
CSNK2A1 P68400 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
NR3C2 P08235 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9231796 0.85 GPR35 (0.56) GPR35BCL2L1HTR2BMAPTTSHR
SCHEMBL12872412 0.85 GPR35 (0.56) GPR35BCL2L1HTR2BMAPTTSHR
SCHEMBL4415767 0.85 HTR2B (0.49) GPR35HTR2BMAPTTSHRALOX15
SCHEMBL1683655 0.85 HTR2B (0.49) GPR35HTR2BMAPTTSHRALOX15
SCHEMBL723266 0.85 HTR2B (0.49) GPR35HTR2BMAPTTSHRALOX15
SCHEMBL5493591 0.84 MAPT (0.46) GPR35POLBHTR2BMAPTTSHR
SCHEMBL10425856 0.82 MAPT (0.52) GPR35HTR2BMAPTTSHRALOX15
SCHEMBL5501011 0.82 GPR35 (0.44) GPR35HTR2BCSNK2A1
SCHEMBL5495521 0.82 MAPT (0.42) HTR2BMAPTTSHRALOX15MAPK1
SCHEMBL12872394 0.80 GPR35 (0.42) GPR35POLBHTR2BMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290434-A Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof 南开大学 2024-07-05 CN claimed
CN-1835937-B Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV 2012-07-18 CN claimed
CN-118290434-A Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof 南开大学 2024-07-05 CN disclosed
CN-1835937-B Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV 2012-07-18 CN disclosed
EP-1656360-B1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2007-08-15 EP disclosed
CN-1835937-A Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2006-09-20 CN disclosed
EP-1656360-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-17 EP disclosed
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JASSEN PHARMACEUTICA N.V. (BE) 2005-01-20 US disclosed
WO-2004113309-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) AR, NR5A1, NR5A2 GPR35 76/4885BCL2L1 4203/4885BAD 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.